Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



1-Star Stocks Poised to Plunge: Derma Sciences?

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, wound care products company Derma Sciences (NASDAQ: DSCI  ) (NASDAQ: DSCI  ) (NASDAQ: DSCI  ) has received a distressing one-star ranking.

With that in mind, let's take a closer look at Derma Sciences and see what CAPS investors are saying about the stock right now.

Derma Sciences facts

Headquarters (founded)

Princeton, N.J. (since 1984)

Market Cap

$150 million


Health care supplies

Trailing-12-Month Revenue

$65.3 million


Chairman/CEO Edward Quilty
CFO John Yetter

Trailing-12-Month Return on Equity



$18.8 million / $0


Covidien (NYSE: COV  )
Johnson & Johnson (NYSE: JNJ  )

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 8% of the 13 members who have rated Derma Sciences believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star zzlangerhans, succinctly summed up the Derma Sciences bear case for our community:

They still lose money every quarter, there's no upward trend in revenues, and they seem to drag out their pipeline development endlessly. The company is now saying they will "begin their phase III program" for DSC127 for diabetic foot ulcers in 12/12. ...

When it finally really does begin, the phase III trial will compare DSC127 with placebo, and there's a good chance of showing stat sig benefit. That won't necessarily translate into commercial viability, however, as there are already many wound treatments for diabetic foot ulcers that do better than placebo. ... I expect significantly more dilution to take place before we see any phase III results for DSC127.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2095380, ~/Articles/ArticleHandler.aspx, 10/26/2016 5:27:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
COV.DL $0.00 Down +0.00 +0.00%
Covidien CAPS Rating: *****
DSCI $4.60 Down -0.10 -2.13%
Derma Sciences CAPS Rating: **
JNJ $114.56 Up +0.60 +0.53%
Johnson and Johnso… CAPS Rating: ****